Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | RXRA | P19793 | 1/20 | 0.79 |
| ▸ | MPC2 | O95563 | 1/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13475125 | 1.00 | PPARG (0.80) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL30640947 | 1.00 | PPARG (0.80) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Hydrochloric Acid SCHEMBL1162844 | 0.99 | PPARG (0.81) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL5172074 | 0.89 | PPARG (0.64) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL29593116 | 0.89 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL4121 | 0.89 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL21844 | 0.89 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL29364546 | 0.89 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1162440 | 0.89 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL503083 | 0.89 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111875598-B | Preparation method of pioglitazone | 白银京宇新药业有限公司 | 2023-10-10 | — | — | CN | claimed |
| CN-111875598-A | Preparation method of pyriformimine | 白银京宇新药业有限公司 | 2020-11-03 | — | — | CN | claimed |
| CN-111875598-B | Preparation method of pioglitazone | 白银京宇新药业有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-111875598-A | Preparation method of pyriformimine | 白银京宇新药业有限公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-103304473-B | The preparation method of imino group pioglitazone and relevant intermediate | 浙江九洲药业股份有限公司 | 2016-07-06 | — | — | CN | disclosed |
| CN-103304473-A | Iminopioglitazone preparation method and relevant intermediate | ZHEJIANG JIUZHOU PHARM CO LTD | 2013-09-18 | — | — | CN | disclosed |
| WO-2012166614-A2 | THIOCARBAMATE AND SULFONAMIDE HYDROXAMATE INHIBITORS OF INSULIN-DEGRADING ENZYME | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2012-12-06 | — | — | WO | disclosed |
| JP-2010208957-A | 5-{4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL}-2-IMINO-4-THIAZOLIDINONE HAVING CRYSTAL STRUCTURE AND METHOD FOR PRODUCING THE SAME | TOKUYAMA CORP | 2010-09-24 | — | — | JP | disclosed |
| JP-2010208957-A | 5-{4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL}-2-IMINO-4-THIAZOLIDINONE HAVING CRYSTAL STRUCTURE AND METHOD FOR PRODUCING THE SAME | TOKUYAMA CORP | 2010-09-24 | — | — | JP | disclosed |
| JP-2010105943-A | MANUFACTURING METHOD OF 5-{4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL}-2,4-THIAZOLIDINEDIONE HYDROCHLORIDE | TOKUYAMA CORP | 2010-05-13 | — | — | JP | disclosed |
| WO-2010015818-A1 | RESPIRATORY DISEASE TREATMENT | ARGENTA DISCOVERY LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
| WO-2005049532-A2 | A PROCESS FOR PURIFICATION | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2005-06-02 | — | — | WO | disclosed |
| US-20050043360-A1 | Method for obtaining pioglitazone as an antidiabetic agent | LECIVA, A.S. (CZ) | 2005-02-24 | — | — | US | disclosed |
| WO-2004108721-A1 | PROCESS FOR THE PREPARATION OF 5-[[4-[2-(5-ETHYL-2-PYRIDINYL)ETHOXY]PHENYL] METHYL]-2,4-THIAZOLIDINEDIONE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004024059-A2 | IMPROVED PROCESS FOR PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES | THEMIS LABORATORIES PRIVATE LIMITED, (IN) | 2004-03-25 | — | — | WO | disclosed |
| EP-1387843-A1 | METHOD FOR OBTAINING PIOGLITAZONE AS AN ANTIDIABETIC AGENT | Leciva, A.S. (CZ) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002088120-A1 | METHOD FOR OBTAINING PIOGLITAZONE AS AN ANTIDIABETIC AGENT | Léciva, a.s. (CZ) | 2002-11-07 | — | — | WO | disclosed |
| EP-0193256-B1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1989-04-05 | — | — | EP | disclosed |
| US-4687777-A | pioglitazone and salts | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-08-18 | — | — | US | disclosed |
| EP-0193256-A1 | Thiazolidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043360-A1 | Method for obtaining pioglitazone as an antidiabetic agent | GLP1R, INSR, CBR3 | PPARG 6/4885CYP3A4 221/4885RXRA 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.